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A B S T R A C T
A Mycobacterium high-density DNA probe array designed to detect rpoB mutations conferring rifampicin
resistance in Mycobacterium tuberculosis was evaluated. The rpoB hybridisation patterns produced by 41
susceptible (RifS) and 59 rifampicin-resistant (RifR) clinical isolates of M. tuberculosis were compared
with the results of conventional dideoxynucleotide sequencing of the rpoB gene. For all the RifR isolates,
the rpoB hybridisation patterns correlated with the rpoB sequencing results. Among the 59 isolates, 11
distinct amino-acid changes were detected by the DNA probe array. Of these, 36 (61%) corresponded to
replacement of the serine residue found in position 531 (S531L in 34 isolates and S531W in two isolates),
16 (27%) affected histidine 526 (five H526D, five H526Y, four H526L, one H526N and one H526R), four
(6.8%) replaced aspartate 516 with a valine, and one (1.7%) replaced glutamine 513 with a leucine.
Deletion of the asparagine residue at position 519 was detected in one isolate susceptible to rifampicin,
but yielding c. 0.1% resistant colonies on rifampicin-containing medium. No mutation was detected in
the rpoB region from one isolate yielding c. 5% of resistant colonies on rifampicin-containing medium.
Finally, a D516Y substitution was detected in association with an unexpected mutation, G523W, not tiled
on the DNA probe array, but which could be detected by analysing the hybridisation pattern obtained
with the wild-type probes covering codon 523. In conclusion, the Mycobacterium probe array is a
promising approach to rapid detection of mutations involved in rifampicin resistance in M. tuberculosis.
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I N T R O D U C T I O N
Rifampicin resistance (RifR) in Mycobacterium
tuberculosis is a serious concern in the event of
tuberculosis diagnosis. Most often, RifR strains are
resistant also to isoniazid, the other major drug
used for tuberculosis treatment. Rapid detection
of RifR in M. tuberculosis is therefore important for
implementation of appropriate treatment and
management of infected patients, particularly
individuals with highly contagious infections
who require isolation to prevent the spread of
resistant strains.
The genetic basis for RifR in M. tuberculosis
comprises mutations in the rpoB gene, which
encodes the b-subunit of RNA polymerase [1,2].
The genetic changes leading to RifR are now well-
characterised. In > 95% of RifR isolates, resistance
is conferred by mutations within the 81-bp motif
of the rpoB gene that corresponds to the 511–533
region of the RNA polymerase b-subunit [1,3,4].
Substitutions affecting amino-acid residues 526
and 531 represent 30% and 50%, respectively, of
the rpoB mutations detected in clinical isolates [2].
Most other mutations involved in clinical resist-
ance to rifampicin are scattered throughout posi-
tions 513–533, and include a large variety of
amino-acid substitutions [5–7].
Several molecular assays have been developed
to screen the rpoB gene for RifR mutations,
including single-strand conformation polymorph-
ism analysis, heteroduplex and mismatch
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analyses, dot spot, DNA sequencing, and other
assays [8–13]. A commercial test, the Inno-LiPa
assay, is available for detection of the four
commonest mutations in clinical isolates (D516V,
H526Y, H526D, S531L) [14,15]. More recently,
real-time PCR coupled with fluorescence detec-
tion has been applied to detection of resistance-
associated mutations in M. tuberculosis [16]. The
method is based on the determination, by fluor-
escent-probe melting profile analysis, of the Tm
value of an amplified rpoB fragment spanning
codons 526 and 531. Although the entire assay can
be completed in 30 min, the method can detect
only the presence of mutations, and cannot define
the exact nucleotide substitution involved [16].
Finally, a new gene chip method of screening for
mutations in bacterial genes has been developed,
relying on hybridisation of the nucleic acid target
to large sets of oligonucleotide probes synthesised
on to a miniaturised glass substrate [17]. Briefly,
two sets of probes are used. One set is based on
the nucleotide sequence of the wild-type rpoB
gene (the wild-type probes), while the second set
corresponds to specific rpoB mutations involved in
RifR (the mutant probes). For every base in a given
sequence, four probes of equal length are synthe-
sised on the array. The interrogated base is located
centrally within the four probes, which have
common 3¢- and 5¢-termini. One of the four probes
is an exact complement to the reference sequence,
while the other three represent the possible single-
base mismatches to the interrogated base [17].
A database representing the entire wild-type
sequence, plus 55 unique rpoB mutations corres-
ponding to 41 distinct substitutions, 11 deletions
and three insertions, is used to analyse the rpoB
region encompassing amino-acid positions 498–
536 of the RNA polymerase b-subunit.
In the present study, a high-density DNA probe
array (DNA chip) was used to detect rpoB muta-
tions associated with RifR in 41 susceptible and
59 resistant M. tuberculosis clinical isolates. The
performance was compared with results obtained
by sequencing of the rpoB gene.
M A T E R I A L S A N D M E T H O D S
Bacterial strains, phenotypic identification and
susceptibility testing
One-hundred clinical isolates of M. tuberculosis (Laboratory of
Bacteriology, Hospital Pitie´-Salpeˆtrie`re, Paris, France) were
tested. Controls were standard strains of M. tuberculosis
(H37Rv), Mycobacterium bovis, Mycobacterium africanum and
Mycobacterium avium. All isolates were grown on Lowenstein–
Jensen (LJ) medium, and were identified by hybridisation with
the AccuProbe test (GenProbe; bioMe´rieux, Marcy-L’Etoile,
France) and by biochemical tests. Rifampicin, rifabutin and
isoniazid susceptibility tests were carried out by the propor-
tion method on LJ medium containing rifampicin 40 mg ⁄L,
rifabutin 4 mg ⁄L and isoniazid 0.2 mg ⁄L, respectively. The
isolates were considered resistant if ‡ 1% of colonies grew on
the antibiotic-containing medium compared with the drug-free
medium. The sample of clinical isolates included 41 RifS and 59
RifR isolates collected routinely between 1994 and 2000. Among
the 41 RifS isolates, only one was resistant to isoniazid. In
contrast, 52 of the 59 RifR isolates were resistant also to isoniazid.
MICs of rifampicin and rifabutin were determined as
described previously [18]. The MIC was defined as the lowest
concentration of drug that inhibited ‡ 99% of growth com-
pared with the drug-free medium.
DNA sequencing of the rpoB gene
DNA was extracted as described previously [17] from colonies
grown on LJ medium. A 391-bp internal fragment of rpoB was
amplified with primers RIFWS1 (5¢-GCGTACGGTCGGC-
GAGCTG-3¢) and RIFWS2 (5¢-CGGGTTGACCCGCGCGTAC-
3¢) in a PCR comprising 40 cycles of 1 min at 94C, 1 min at
60C and 1 min at 72C. Amplified DNA was purified with
Amicon columns (Millipore, Bedford, MA, USA). Direct
sequencing of amplicons was performed with an ABI PRISM
Ready Reaction DyeDeoxy Terminator Cycle Sequencing FS kit
(Applied Biosystems, Branchberg, NJ, USA), following the
manufacturer’s instructions.
Probe array testing
Target preparation and amplification of the M. tuberculosis rpoB
RifR locus were carried out with freshly grown colonies of the
clinical isolates, following the procedure described by Troesch
et al. [17] with the following modifications. PCR was per-
formed with Fast Start Taq DNA polymerase (Roche Molecular
Biochemicals, Mannheim, Germany) in a final volume of 50 lL
containing 5 lL 10· amplification buffer, 0.4 lL dNTP mix
(25 mM each), 0.4 lL enzyme (2 U), 5 lL bacterial lysate
containing the DNA target, and 1.5 lL of each primer (10 lM)
[17]. Amplification in a GeneAmp 9600 thermal cycler
(Applied Biosystems) comprised 5 min at 95 C followed by
35 cycles of 30 s at 94 C, 30 s at 68 C and 45 s at 72 C,
followed by a final extension at 72 C for 7 min. The amplicons
were then labelled with biotin for 10 min at 95 C with a
proprietary labelling mix (bioMe´rieux), and cleaved subse-
quently for 10 min in acidic conditions. Unincorporated biotin
was removed by purification on a 6S Qiavac column (Qiagen,
Hilden, Germany), following the manufacturer’s instructions.
Probe array hybridisation and analysis
Labelled target (100 lL) was diluted in 400 lL of hybridisation
buffer (see below), denatured at 95 C for 10 min, and then
loaded on to a prototype probe array (Affymetrix, Santa Clara,
CA, USA). After incubation for 30 min at 50 C in hybridisa-
tion buffer (0.9 M NaCl, 60 mM NaH2PO4, 6 mM EDTA
pH 7.4, Triton X-100 0.05% v ⁄v, 3 M betaine, 5 mM DTAB
290 Clinical Microbiology and Infection, Volume 10 Number 4, April 2004
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 289–294
(dodecyl trimethyl ammonium bromide)), the probe array was
washed twice in 0.45 M NaCl, 30 mM NaH2PO4, 3 mM EDTA
pH 7.4, Triton X-100 0.005% v ⁄v at 30 C. Staining of the probe
array was for 10 min in a solution comprising 300 lL 2 M
2-(N-morpholino)-ethane-sulphonic acid, 6 lL bovine serum
albumin (50 mg ⁄mL) and 6 lL streptavidin–R-phycoerythrin
conjugate (300 lg ⁄mL; Dako, Glostrup, Denmark). After a
washing step in 6 · SSPE (0.9 M NaCl, 60 mM NaH2PO4,
6 mM EDTA) plus Tween 0.01% v ⁄v, the fluorescent signal
emitted by the target bound to the array was detected at a pixel
resolution of 3 lm with a GeneArray scanner (Hewlett-
Packard, Palo Alto, CA, USA). Probe array cell intensities,
nucleotide base call, mutation determination and reports were
generated by functions available on the GeneChip software
(Affymetrix).
R E S U L T S
The performance of the M. tuberculosis rpoB probe
array was first verified by using four reference
strains. As expected, no hybridisation signal was
obtained from M. avium, while M. tuberculosis
(H37Rv), M. bovis and M. africanum produced a
sequence base call of 100% with the wild-type
M. tuberculosis complex rpoB sequence (data not
shown).
Analysis of the 41 RifS clinical isolates included
in the present study (rifampicin and rifabutin
MICs of £ 0.5 mg ⁄L and 0.01 mg ⁄L, respectively)
produced probe array results concordant with
those obtained by DNA sequencing. Thus, 40 of
41 RifS isolates yielded clear and strong hybrid-
isation signals with the wild-type probe tiles (data
not shown). One RifS isolate (31B) yielded c. 0.1%
of resistant colonies when grown on LJ medium
supplemented with rifampicin, and a mutation
corresponding to deletion of the asparagine resi-
due found at position 519 (delN519; Table 1) was
detected clearly by the probe array and by DNA
sequencing.
The RifR M. tuberculosis clinical isolates for
which MICs were determined (Q513L, H526Y,
H526D, H526R, S531L, S531W) had high MICs
of rifampicin (64–512 mg ⁄L) and rifabutin
(2–32 mg ⁄L). In all cases, results obtained with
the rpoB probe array for the 59 RifR isolates
corresponded to nucleotide sequence data. The
amino-acid substitution S531L was detected in 34
isolates, accounting for 57.6% of the RifR isolates.
Another substitution affecting codon 531 (S531W)
was found in two (3.4%) isolates. Amino-acid
substitutions in the 526 position were found in
27% of isolates; H526D and H526Y were each
found in five (8.4%) RifR isolates, while H526L,
H526N and H526R were found in four isolates
(6.8%), one isolate (1.7%) and one (1.7%) isolate,
respectively (Table 1). Among the other detected
substitutions, four (6.8%) corresponded to D516V
and one (1.7%) to Q513L. Finally, no mutation
was detected by either array technology or DNA
sequencing in the rpoB gene of one phenotypically
resistant isolate (50A) that yielded c. 5% of
resistant colonies on LJ medium (Table 1).
The ability to detect a point mutation not
included in the probe array was demonstrated
with isolate 9B, which had a double substitution
D516Y–G523W (Table 1). For the first amino-acid
substitution, D516Y, the mutant probes included
on the array identified correctly the TAC codon
determining a tyrosine (Y) in position 516 (codon
516 in Fig. 1a). With regard to the second substi-
tution identified in isolate 9B (Gly523Trp), the
corresponding mutation was not tiled on the
Table 1. Mycobacterium tuberculosis
rpoB wild-type and mutant isolates
analysed with the Mycobacterium
rpoB probe array
Clinical
isolate
Resistance
phenotypea
Rfp MICb
(mg ⁄L)
Rbt MIC
(mg ⁄L)
Amino-acid
substitution
Nucleotide
substitution
Total number
of isolates
harbouring
the mutation
H37Rv S 0.25 0.01 wt – 1
70A S 0.12 0.01 wt – 40
31B S (0.1%)b ND ND delN519 delAAC 1
50A R (5%)b ND ND wt – 1
43A R 256 8 Q513L CAA ﬁ CTA 1
9B R ND ND D516Y–G523W GAC ﬁ TAC–GGG ﬁ TGG 1
4B R ND ND D516V GAC ﬁ GTC 4
3B R 128–512 16–32 H526Y CAC ﬁ TAC 5
8B R 128–512 8 H526D CAC ﬁ GAC 5
51B R ND ND H526L CAC ﬁ CTC 4
33A R ND ND H526N CAC ﬁ AAC 1
42B R 512 32 H526R CAC ﬁ CGC 1
35B R 64–512 2–16 S531L TCG ﬁ TTG 34
23B R 256 16 S531W TCG ﬁ TGG 2
aS, susceptible to rifampicin; R, resistant to rifampicin.
bPercentage of resistant colonies shown in parentheses.
del, deletion; ND, not determined; Rfp, rifampicin; Rbt, rifabutin; wt, wild-type.
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prototype array used in the present study. Nev-
ertheless, the sequence TGG coding for the
G523W substitution could be identified from the
wild-type probes covering the 523 codon region.
Indeed, at the point mutation position, a strong
hybridisation signal was produced with the TGG
probe complementary to the mutant target, such
that the G ﬁ T mutation responsible for the
G523W substitution in isolate 9B could be iden-
tified clearly (codon 523 in Fig. 1b). Moreover, at
the positions adjacent to the point mutation, a
marked decrease in hybridisation signals oc-
curred (see Fig. 1b) because there was a one-base
mismatch in all the wild-type probes overlapping
region 523 with respect to the mutant target
sequence.
D I S C U S S I O N
Apart from DNA sequencing, most genotypic
methods available to date for molecular detection
of RifR are restricted to identification of only the
most relevant mutations in the rpoB gene, such
that their efficiency can vary depending on the
genetic diversity of the mutations conferring RifR
in different geographical contexts. By testing the
entire wild-type sequence and the presence of a
wide variety of mutations within the 114-bp
hyper-variable rpoB region, the GeneChip probe
array technology represents a promising alternat-
ive for detecting RifR in M. tuberculosis. In the
present study, 12 distinct rpoB mutations were
identified correctly in clinical isolates, and the
hybridisation results obtained with the probe
array showed good correlation with DNA sequen-
cing results. Although the number of mutations
tested in the present study was limited, the
M. tuberculosis GeneChip array was efficient in
detecting not only the most frequent mutations
found in positions 526 and 531, but also mutations
found more rarely, such as those affecting codons
513 and 516. Moreover, the results suggested that
the characteristic hybridisation pattern obtained
for unexpected mutations not included in the set
of mutant probes tiled on the array can be used as
a means of detecting new mutations (e.g.,
G2523W). It could be argued that additional
studies are required to validate the ability of the
system to detect infrequent resistance mutations
in different geographical settings. Nevertheless,
with the GeneChip approach, every base in the
wild-type sequence is tested systematically, so the
method has the potential to detect any nucleotide
variation in the rpoB resistance-determining core
sequence. In this sense, the genetic diversity
characterising the rpoB mutations does not limit
the performance of the method, and it is likely
that the GeneChip array is also efficient in
detecting minor mutations not represented in
the collection of clinical isolates tested.
The mutation frequencies found in the present
study for the two positions 526 and 531 were
similar to those reported previously by other
investigators, and confirm that most (88%) of the
substitutions occur in codons 526 and 531, which
are associated generally with a high level of RifR
[2,15,19]. A deletion of the asparagine residue
found at position 519 was identified in a RifS
isolate yielding c. 0.1% of resistant colonies;
Fig. 1. Detection of the Mycobacterium tuberculosis rpoB
D516Y–G523W double mutation with the M. tuberculosis
rpoB probe array. The signal intensities at each interro-
gated position for the four different bases are shown for
the two rpoB regions encompassing residues 516 (a) and
523 (b). These were obtained with the rpoB probes
designed to detect specifically the D516Y mutation (a)
and the wild-type M. tuberculosis rpoB region (b). The rpoB
nucleotide sequence is shown below the signal inten-
sity results. The two amino-acid substitutions
D516Y(GAC ﬁ TAC) and G523W(GGG ﬁ TGG) are
boxed.
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however, a direct correlation between this single-
point deletion and the minor population of
resistant colonies cannot be assumed, and the
presence of another mechanism of RifR in this
isolate cannot be excluded. In addition, no muta-
tion in the rpoB gene was detected in a second
resistant isolate yielding c. 5% of resistant colon-
ies. For this discrepant isolate, either a mutation
outside the 81-bp hypervariable rpoB region, or a
different mechanism of resistance, may account
for the RifR colonies. In this context, it is accepted
generally that c. 5% of rpoB mutations conferring
RifR occur outside the 511–533 region of the b-
subunit of RNA polymerase [20]. Finally, it
should be noted that G523W has been reported
only once previously in a RifR clinical isolate with
three missense mutations D516Y–G523W–T525I
[21]. In isolate 9B, G523W also occurred in
association with mutation D516Y, which is one
of the four mutations encountered most fre-
quently in RifR clinical isolates (Table 1) [5,6]. It
is therefore tempting to speculate that G523W is
not a critical mutation for RifR.
In conclusion, the results of this study suggest
that the Mycobacterium GeneChip probe array has
the potential for rapid identification of sequence
variations involved in RifR in M. tuberculosis
clinical isolates. This genotypic method has sev-
eral advantages. First, the test is rapid (8 h).
Second, the probe array can screen for a very
large panel of mutations, and even non-tiled
substitutions can be determined by detecting a
specific hybridisation profile at the level of the
wild-type probes, highlighting the fact that the
efficiency of the GeneChip technology should not
be weakened by the occurrence of new point
mutations. Finally, the method can be extended to
the analysis of genes responsible for resistance to
other drugs, and is the first system able to identify
simultaneously, in the same assay, 54 distinct
species of mycobacteria [17]. In the context of
using this molecular approach for direct analysis
of clinical samples, the rpoB GeneChip probe
array should greatly simplify and accelerate
identification and the determination of antibiotic
resistance in routine laboratories.
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